Altimmune, Inc. (ALT)
NasdaqGM
Price as at 30 Sept 2026, 16:15 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Altimmune, Inc. trades at $2.93. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Marshall Wace, MARSHALL WACE, LLP$20.80M · 0.0% of book
- Andreas Halvorsen, VIKING GLOBAL INVESTORS LP$20.37M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$10.06M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$7.24M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.71M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ALT?
10 of the institutions we track reported a position in ALT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ALT data?
Fundamentals for ALT come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:15 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ALT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.